Furthermore, our study suggests that elevating SORLA levels, as achieved in our case by blocking PKCι/λ to disrupt the SORLA-βARR2 interaction, is an effective strategy to reduce Aβ production and alleviate AD-related phenotypes. The gene discussed is SORL1; the disease is Alzheimer disease.